Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

Q: What does this research mean for the field?

Bempegaldesleukin (NKTR-214) selectively depletes intratumoral regulatory T cells and synergizes with T cell-mediated anti-cancer therapies. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

Meenu Sharma; Hiep Khong; Faisal Fa’ak; Salah-Eddine Bentebibel; Louise M.E. Janssen; Brent C. Chesson; Caitlin Creasy; Marie-Andrée Forget; Laura M. Kahn; Barbara Pazdrak; Binisha Karki; Yared Hailemichael; Manisha Singh; Christina Vianden; Srinivas Vennam; Uddalak Bharadwaj; David J. Tweardy; Cara Haymaker; Chantale Bernatchez; Shixia Huang; Kimal Rajapakshe; Cristian Coarfa; Michael E. Hurwitz; Mario Sznol; Patrick Hwu; Ute Hoch; Murali K. Addepalli; Deborah H. Charych; Jonathan Zalevsky; Adi Diab; Willem W. Overwijk

doi:10.1038/s41467-020-14471-1

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Teff-associated cytokines IFN-γ and TNF-α. These findings demonstrate that NKTR-214 synergizes with T cell-mediated anti-cancer therapies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sharma et al. (2020) studied this question.

synapsesocial.com/papers/6a0874c9df3db8739810973f https://doi.org/10.1038/s41467-020-14471-1

View Full Paper

Ask AI

Bookmark

Share

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

Ask about this paper

Abstract

Discussion

Cite This Study

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading